The 8 analysts offering 12-month price forecasts for BioCryst Pharmaceuticals Inc have a median target of 7.50, with a high estimate of 13.00 and a low estimate of 4.50. The median estimate represents a +95.31% increase from the last price of 3.84.
The current consensus among 10 polled investment analysts is to Buy stock in BioCryst Pharmaceuticals Inc. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.26
Reporting Date Nov 05
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.